Haihe Biopharma Co., a Chinese pharmaceutical company specialized in innovative oncology drugs, has secured a US$146.6 million new round of investment led by China-focused private equity firm Huagai Capital, said Haihe Biopharma in a statement released on Monday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 3 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription for $359
Enjoy comprehensive and exclusive data you can't find elsewhere!Subscribe for $359
Already have an account or paid subscription?